Department of Dermatology and Skin Science, University of British Columbia, Surrey, BC, Canada.
Department of Dermatology, Hôpital du Haut-Richelieu, Saint-Jean-sur-Richelieu, QC, Canada.
J Cosmet Dermatol. 2021 Jul;20(7):2148-2155. doi: 10.1111/jocd.14116. Epub 2021 Apr 24.
Minéral 89 (M89), comprised of 89% Vichy mineralizing water and hyaluronic acid, has been formulated to help strengthen and restore skin barrier.
Assess tolerance and efficacy of M89 in post-esthetic procedures and dry skin-related facial dermatoses.
Adults post-esthetic procedure or presenting with inflammatory dermatoses (47 subjects; mean age 40.9 ± 13.2 years; any Fitzpatrick or skin phototype), applied M89 for 4 weeks, once or twice daily, as an adjuvant treatment. Information on clinical signs and subject-reported symptoms, skin characteristics, tolerance, and subject and investigator satisfaction were collected.
Following 4 weeks of M89 use, significant decreases with complete resolution of erythema (27.6%), desquamation (29.8%), irritation (32%), and skin dehydration (35.8%), as compared to baseline signs and symptoms, were observed. Overall grading improvements for erythema (84.8%; p < 0.001), desquamation (91.7%; %; p < 0.003), irritation (91.7%; %; p < 0.015), and skin hydration (46.2%; p < 0.015) were noted. There was no significant improvement in papules and pustules. Evaluation of subjective signs demonstrated significant decreases in skin sensations such as burning (-73%; p < 0.0001), itching (-71%; p < 0.0001), stinging-tingling (-66.7%; p < 0.0001), as well as in skin dryness (-60%; p < 0.0001). M89 texture was rated very pleasant by 90% of patients. Investigators assessed M89 tolerance to be either good or very good (93%), and satisfactory or highly satisfactory impact on patient's skin (91.5%).
M89 is a highly tolerable adjuvant treatment that significantly improved clinical signs and symptoms related to a compromised skin barrier in various facial dermatoses and post-aesthetic procedures.
Mineral 89(M89)由 89%的薇姿矿物质水和透明质酸组成,旨在帮助增强和修复皮肤屏障。
评估 M89 在美容程序后和与干燥皮肤相关的面部皮肤病中的耐受性和疗效。
成年人接受美容程序或出现炎症性皮肤病(47 例;平均年龄 40.9±13.2 岁;任何 Fitzpatrick 或皮肤光型),每天使用 M89 进行 1 或 2 次辅助治疗,持续 4 周。收集临床体征和患者报告的症状、皮肤特征、耐受性以及患者和研究者的满意度信息。
使用 M89 4 周后,与基线体征和症状相比,观察到红斑(27.6%)、脱屑(29.8%)、刺激(32%)和皮肤脱水(35.8%)显著减少并完全消退。红斑(84.8%;p<0.001)、脱屑(91.7%;%;p<0.003)、刺激(91.7%;%;p<0.015)和皮肤水合作用(46.2%;p<0.015)的总体评分均有显著改善。丘疹和脓疱无显著改善。主观体征评估显示,皮肤感觉如烧灼感(-73%;p<0.0001)、瘙痒感(-71%;p<0.0001)、刺痛感(-66.7%;p<0.0001)以及皮肤干燥感(-60%;p<0.0001)均显著降低。90%的患者认为 M89 的质地非常宜人。研究者评估 M89 的耐受性为良好或非常好(93%),对患者皮肤的影响为满意或非常满意(91.5%)。
M89 是一种高度耐受的辅助治疗方法,可显著改善各种面部皮肤病和美容程序后的皮肤屏障受损相关的临床体征和症状。